Search
Lyell Immunopharma Inc
LYELAdd to Watchlist
14.050USD
+1.080+8.33%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
4.15BMarket Cap
LossP/E TTM
More Details of Lyell Immunopharma Inc Company
Lyell Immunopharma, Inc. is a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with hematologic malignancies and solid tumors. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The Company has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Lyell Immunopharma Inc Info
Ticker SymbolLYEL
Company nameLyell Immunopharma Inc
IPO dateJun 17, 2021
CEOSeely (Lynn)
Number of employees300
Security typeOrdinary Share
Fiscal year-endJun 17
Address201 Haskins Way
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16506950677
Websitehttps://lyell.com/
Ticker SymbolLYEL
IPO dateJun 17, 2021
CEOSeely (Lynn)
Company Executives of Lyell Immunopharma Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Lynn Seely, M.D.
Dr. Lynn Seely, M.D.
President, Chief Executive Officer, Interim Principal Financial Officer, Director
President, Chief Executive Officer, Interim Principal Financial Officer, Director
37.28K
-1.04%
Dr. Sumant Ramachandra, M.D., Ph.D.
Dr. Sumant Ramachandra, M.D., Ph.D.
Independent Director
Independent Director
10.00K
--
Dr. Otis W. Brawley, M.D.
Dr. Otis W. Brawley, M.D.
Independent Director
Independent Director
1.78K
--
Dr. Richard D. Klausner, M.D.
Dr. Richard D. Klausner, M.D.
Chairman of the Board
Chairman of the Board
--
--
Mr. Stephen Hill
Mr. Stephen Hill
Chief Operating Officer
Chief Operating Officer
--
--
Ms. Catherine (Cathy) Friedman
Ms. Catherine (Cathy) Friedman
Lead Independent Director
Lead Independent Director
--
--
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
--
--
Mr. William J. (Bill) Rieflin
Mr. William J. (Bill) Rieflin
Independent Director
Independent Director
--
--
Dr. Gary Lee, Ph.D.
Dr. Gary Lee, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Mark Bachleda
Dr. Mark Bachleda
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Lynn Seely, M.D.
Dr. Lynn Seely, M.D.
President, Chief Executive Officer, Interim Principal Financial Officer, Director
President, Chief Executive Officer, Interim Principal Financial Officer, Director
37.28K
-1.04%
Dr. Sumant Ramachandra, M.D., Ph.D.
Dr. Sumant Ramachandra, M.D., Ph.D.
Independent Director
Independent Director
10.00K
--
Dr. Otis W. Brawley, M.D.
Dr. Otis W. Brawley, M.D.
Independent Director
Independent Director
1.78K
--
Dr. Richard D. Klausner, M.D.
Dr. Richard D. Klausner, M.D.
Chairman of the Board
Chairman of the Board
--
--
Mr. Stephen Hill
Mr. Stephen Hill
Chief Operating Officer
Chief Operating Officer
--
--
Ms. Catherine (Cathy) Friedman
Ms. Catherine (Cathy) Friedman
Lead Independent Director
Lead Independent Director
--
--
FAQs
Who are the top five shareholders of Lyell Immunopharma Inc?
The top five shareholders of Lyell Immunopharma Inc are: Dr. Lynn Seely, M.D.
How many institutions hold shares of Lyell Immunopharma Inc (LYEL)?
As of 2026Q1, 256 institutions hold shares of Lyell Immunopharma Inc, with a combined market value of approximately 13.43M, accounting for 57.58% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 1891871.00.